SCM
INDV icon

Sterling Capital Management’s Indivior Pharmaceuticals INDV Stock Holding History

Sterling Capital Management’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.6K Sell
648
-625
-49% -$22.7K ﹤0.01% 1765
2026
Q1 		$38.8K Sell
1,273
-461
-27% -$15.2K ﹤0.01% 1752
2025
Q4 		$62.2K Buy
1,734
+236
+16% +$7.21K ﹤0.01% 1721
2025
Q3 		$36.1K Buy
1,498
+761
+103% +$15.9K ﹤0.01% 1878
2025
Q2 		$10.9K Buy
+737
New +$8.58K ﹤0.01% 2078

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sterling Capital Management's INDV Position: Q2 2026 in Review

Sterling Capital Management reduced its Indivior Pharmaceuticals (INDV) stake by 49% in Q2 2026, selling an estimated $22.7K and leaving 648 shares worth $26.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1765.

Sterling Capital Management first reported a position in INDV in Q2 2025 and has held it in 5 quarters since. The position peaked at $62.2K in Q4 2025. 339 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Sterling Capital Management held 648 shares of Indivior Pharmaceuticals worth $26.6K as of Q2 2026.
  • Sterling Capital Management sold 625 Indivior Pharmaceuticals shares in Q2 2026, an estimated $22.7K.
  • Indivior Pharmaceuticals made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #1765 holding.
  • Sterling Capital Management first reported a position in Indivior Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Sterling Capital Management's Indivior Pharmaceuticals position peaked at $62.2K in Q4 2025.
  • 339 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.